NASDAQ:BNOX Bionomics (BNOX) Stock Price, News & Analysis $0.25 +0.01 (+4.20%) (As of 12/23/2024 05:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Bionomics Stock (NASDAQ:BNOX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bionomics alerts:Sign Up Key Stats Today's Range$0.24▼$0.2950-Day Range$0.19▼$0.4952-Week Range$0.18▼$1.60Volume6.84 million shsAverage Volume2.85 million shsMarket Capitalization$4.47 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company OverviewBionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.Read More… Bionomics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks56th Percentile Overall ScoreBNOX MarketRank™: Bionomics scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBionomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBionomics has only been the subject of 1 research reports in the past 90 days.Read more about Bionomics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bionomics are expected to grow in the coming year, from ($1.03) to ($0.42) per share.Price to Book Value per Share RatioBionomics has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.27% of the outstanding shares of Bionomics have been sold short.Short Interest Ratio / Days to CoverBionomics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bionomics has recently increased by 4.19%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBionomics does not currently pay a dividend.Dividend GrowthBionomics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.27% of the outstanding shares of Bionomics have been sold short.Short Interest Ratio / Days to CoverBionomics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bionomics has recently increased by 4.19%, indicating that investor sentiment is decreasing. News and Social Media3.1 / 5News Sentiment0.57 News SentimentBionomics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Bionomics this week, compared to 0 articles on an average week.Search Interest12 people have searched for BNOX on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat Follows3 people have added Bionomics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bionomics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.69% of the stock of Bionomics is held by insiders.Percentage Held by InstitutionsOnly 15.90% of the stock of Bionomics is held by institutions.Read more about Bionomics' insider trading history. Receive BNOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Email Address BNOX Stock News HeadlinesBionomics Ltd – ADR trading halted, news pendingDecember 24 at 1:06 AM | markets.businessinsider.comBionomics (NASDAQ:BNOX) Shares Down 4.5% - Time to Sell?December 20, 2024 | americanbankingnews.comThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… December 25, 2024 | Crypto 101 Media (Ad)Bionomics Limited Receives Court Approval for Re-Domiciliation Scheme to Neuphoria Therapeutics Inc.December 19, 2024 | nasdaq.comBionomics Ltd: Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-DomiciliationDecember 18, 2024 | finanznachrichten.deBionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-DomiciliationDecember 16, 2024 | globenewswire.comBionomics Ltd: Results of Scheme MeetingDecember 14, 2024 | finanznachrichten.deResults of Scheme MeetingDecember 12, 2024 | globenewswire.comSee More Headlines BNOX Stock Analysis - Frequently Asked Questions How have BNOX shares performed this year? Bionomics' stock was trading at $1.48 on January 1st, 2024. Since then, BNOX shares have decreased by 82.9% and is now trading at $0.2531. View the best growth stocks for 2024 here. When did Bionomics IPO? Bionomics (BNOX) raised $20 million in an initial public offering (IPO) on Thursday, December 16th 2021. The company issued 1,622,000 shares at $12.35 per share. How do I buy shares of Bionomics? Shares of BNOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bionomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bionomics investors own include Meta Platforms (META), PayPal (PYPL), Intel (INTC), ChargePoint (CHPT), CRISPR Therapeutics (CRSP) and NVIDIA (NVDA). Company Calendar Today12/25/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BNOX CUSIPN/A CIK1191070 Webwww.bionomics.com.au Phone088-150-7400FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+3,060.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.30 Quick Ratio3.30 Sales & Book Value Annual Sales$10,000.00 Price / Sales446.82 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book0.19Miscellaneous Outstanding Shares17,654,000Free Float17,532,000Market Cap$4.47 million OptionableNot Optionable Beta0.27 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:BNOX) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bionomics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bionomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.